tiprankstipranks
Trending News
More News >
DiaSorin S.p.A. (IT:DIA)
:DIA
Advertisement

DiaSorin S.p.A. (DIA) AI Stock Analysis

Compare
13 Followers

Top Page

IT:DIA

DiaSorin S.p.A.

(LSE:DIA)

Rating:65Neutral
Price Target:
€99.00
▲(16.22% Upside)
DiaSorin S.p.A. demonstrates strong financial performance with solid profitability and effective cash flow management, which is a significant positive factor. However, technical analysis indicates bearish trends, and the valuation suggests the stock might be overvalued, which are notable risks. The absence of impactful earnings call data or corporate events leaves these strengths and risks as the primary influencers of the overall score.
Positive Factors
Financial Performance
DiaSorin reported 4Q results which were a slight beat vs Consensus on Topline and EBITDA, starting the year on a solid footing backdrop considered.
Growth Prospects
Management also pointed to ~25% combined yoy growth for the Verigene and LIAISON PLEX to around €75m, which implies low-teens growth for FY25 in Molecular Diagnostics for FY25, which serves as a solid departure point into FY25.
Negative Factors
Geographical Performance
European growth slowed to 4% CER, with US growing 15%, effectively normalising above average growth driven by high market share tests.

DiaSorin S.p.A. (DIA) vs. iShares MSCI Italy ETF (EWI)

DiaSorin S.p.A. Business Overview & Revenue Model

Company DescriptionDiaSorin S.p.A. is a global leader in the field of in vitro diagnostics, specializing in the development, production, and commercialization of diagnostic tests and systems. The company operates primarily in the medical diagnostics sector, focusing on areas such as infectious diseases, oncology, and endocrinology. DiaSorin offers a wide range of products, including immunodiagnostic assays, molecular diagnostics, and proprietary laboratory systems, which enable healthcare professionals to provide accurate and timely diagnoses.
How the Company Makes MoneyDiaSorin generates revenue primarily through the sale of its diagnostic products and systems to hospitals, laboratories, and healthcare providers worldwide. The company's revenue model is driven by the recurring nature of diagnostic testing, which leads to ongoing sales of consumables such as test kits and reagents. Key revenue streams include the sale of immunoassays, molecular tests, and the related instrumentation. Additionally, DiaSorin benefits from partnerships with healthcare organizations and research institutions, which can enhance its market reach and product development. The company also invests in R&D to innovate and expand its product offerings, ensuring a steady stream of new products that can contribute to its earnings.

DiaSorin S.p.A. Financial Statement Overview

Summary
DiaSorin S.p.A. is financially sound with strong profitability, effective cash flow generation, and a stable balance sheet. The company has demonstrated resilience in revenue growth and maintains a strategic balance between debt and equity, positioning it well for future growth and stability in the medical diagnostics industry.
Income Statement
82
Very Positive
DiaSorin S.p.A. exhibits strong profitability with a consistent gross profit margin of approximately 66% and a stable net profit margin around 16%. Revenue growth has shown resilience, recovering from a decline in 2022 to a growth of 3.2% in 2024. EBIT and EBITDA margins also reflect robust operational efficiency, with EBIT at 23% and EBITDA at 31% in 2024.
Balance Sheet
78
Positive
The company's balance sheet shows solid equity with a debt-to-equity ratio of 0.53, indicating prudent leverage. Return on equity has improved to 10.4% in 2024, showcasing effective shareholder value creation. The equity ratio remains healthy at 59.5%, reflecting financial stability and reduced risk exposure.
Cash Flow
85
Very Positive
DiaSorin S.p.A. demonstrates strong cash flow management, with a free cash flow growth of 34.9% in 2024. The operating cash flow to net income ratio is robust at 1.92, and the free cash flow to net income ratio stands at 1.92, indicating efficient conversion of profits into cash flows.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.21B1.19B1.15B1.36B1.24B881.30M
Gross Profit793.93M781.00M741.19M900.61M824.77M602.90M
EBITDA330.50M399.04M333.40M479.71M504.56M383.62M
Net Income194.10M188.10M159.85M240.91M310.97M247.87M
Balance Sheet
Total Assets2.61B3.30B3.21B3.41B3.23B1.25B
Cash, Cash Equivalents and Short-Term Investments0.00378.92M378.75M384.19M403.02M339.88M
Total Debt672.00M1.01B1.19B1.35B1.40B34.66M
Total Liabilities928.00M1.51B1.67B1.89B1.86B290.13M
Stockholders Equity1.68B1.80B1.54B1.52B1.37B954.68M
Cash Flow
Free Cash Flow289.73M239.07M266.20M275.65M283.29M229.74M
Operating Cash Flow354.92M358.78M311.66M389.34M400.66M304.56M
Investing Cash Flow-80.97M-49.81M-29.10M-231.95M-1.61B-73.02M
Financing Cash Flow-221.66M-259.13M-235.96M-333.04M1.26B-40.89M

DiaSorin S.p.A. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price85.18
Price Trends
50DMA
88.96
Positive
100DMA
91.44
Negative
200DMA
95.80
Negative
Market Momentum
MACD
-0.41
Negative
RSI
63.80
Neutral
STOCH
87.26
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:DIA, the sentiment is Neutral. The current price of 85.18 is below the 20-day moving average (MA) of 85.48, below the 50-day MA of 88.96, and below the 200-day MA of 95.80, indicating a neutral trend. The MACD of -0.41 indicates Negative momentum. The RSI at 63.80 is Neutral, neither overbought nor oversold. The STOCH value of 87.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IT:DIA.

DiaSorin S.p.A. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
€4.95B24.3212.16%1.33%4.69%15.79%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
€10.88B26.5022.16%
73
Outperform
€465.17M28.10
2.06%17.78%63.72%
€431.84M19.216.75%
79
Outperform
€527.11M5.09
4.68%16.92%
€43.81M7.76
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IT:DIA
DiaSorin S.p.A.
85.18
-19.14
-18.35%
GB:0KBS
Recordati Industria Chimica e Farmaceutica SPA
53.00
1.74
3.39%
IT:PHN
PharmaNutra SpA
48.55
-2.21
-4.35%
DE:GHC
Garofalo Health Care S.P.A.
4.72
-0.47
-9.06%
IT:GPI
GPI SpA
18.18
6.69
58.22%
IT:SVS
Svas Biosana S.p.A.
8.20
0.49
6.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 29, 2025